Week In Review: Keymed Completes $378 Million IPO In Hong Kong For Antibody Drugs
July 10, 2021 at 14:46 PM EDT
Keymed Biosciences of Chengdu completed a $378.5 million Hong Kong IPO to develop its portfolio of antibody candidates. The company priced the IPO at the top end of the range, and its shares rose 28% in its first trading session.
